These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule. McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604 [TBL] [Abstract][Full Text] [Related]
3. NK cell triggering by the human costimulatory molecules CD80 and CD86. Wilson JL; Charo J; Martín-Fontecha A; Dellabona P; Casorati G; Chambers BJ; Kiessling R; Bejarano MT; Ljunggren HG J Immunol; 1999 Oct; 163(8):4207-12. PubMed ID: 10510357 [TBL] [Abstract][Full Text] [Related]
4. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Slavik JM; Hutchcroft JE; Bierer BE Immunol Res; 1999; 19(1):1-24. PubMed ID: 10374692 [TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. Matsui T; Kurokawa M; Kobata T; Oki S; Azuma M; Tohma S; Inoue T; Yamamoto K; Nishioka K; Kato T J Immunol; 1999 Apr; 162(7):4328-35. PubMed ID: 10201965 [TBL] [Abstract][Full Text] [Related]
6. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4. Höllsberg P; Scholz C; Anderson DE; Greenfield EA; Kuchroo VK; Freeman GJ; Hafler DA J Immunol; 1997 Nov; 159(10):4799-805. PubMed ID: 9366404 [TBL] [Abstract][Full Text] [Related]
7. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. Tao X; Constant S; Jorritsma P; Bottomly K J Immunol; 1997 Dec; 159(12):5956-63. PubMed ID: 9550393 [TBL] [Abstract][Full Text] [Related]
8. IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. Nikcevich KM; Gordon KB; Tan L; Hurst SD; Kroepfl JF; Gardinier M; Barrett TA; Miller SD J Immunol; 1997 Jan; 158(2):614-21. PubMed ID: 8992975 [TBL] [Abstract][Full Text] [Related]
9. Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. Chen C; Gault A; Shen L; Nabavi N J Immunol; 1994 May; 152(10):4929-36. PubMed ID: 7513726 [TBL] [Abstract][Full Text] [Related]
10. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. Greenfield EA; Howard E; Paradis T; Nguyen K; Benazzo F; McLean P; Höllsberg P; Davis G; Hafler DA; Sharpe AH; Freeman GJ; Kuchroo VK J Immunol; 1997 Mar; 158(5):2025-34. PubMed ID: 9036945 [TBL] [Abstract][Full Text] [Related]
11. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Pentcheva-Hoang T; Egen JG; Wojnoonski K; Allison JP Immunity; 2004 Sep; 21(3):401-13. PubMed ID: 15357951 [TBL] [Abstract][Full Text] [Related]
12. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Carreno BM; Collins M Annu Rev Immunol; 2002; 20():29-53. PubMed ID: 11861596 [TBL] [Abstract][Full Text] [Related]
13. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. Yang G; Hellström KE; Hellström I; Chen L J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183 [TBL] [Abstract][Full Text] [Related]
14. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection. Elloso MM; Scott P J Immunol; 1999 Jun; 162(11):6708-15. PubMed ID: 10352289 [TBL] [Abstract][Full Text] [Related]
15. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960 [TBL] [Abstract][Full Text] [Related]
16. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. Linsley PS; Bradshaw J; Urnes M; Grosmaire L; Ledbetter JA J Immunol; 1993 Apr; 150(8 Pt 1):3161-9. PubMed ID: 7682233 [TBL] [Abstract][Full Text] [Related]
17. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. Behrens L; Kerschensteiner M; Misgeld T; Goebels N; Wekerle H; Hohlfeld R J Immunol; 1998 Dec; 161(11):5943-51. PubMed ID: 9834075 [TBL] [Abstract][Full Text] [Related]
18. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. Freeman GJ; Lombard DB; Gimmi CD; Brod SA; Lee K; Laning JC; Hafler DA; Dorf ME; Gray GS; Reiser H J Immunol; 1992 Dec; 149(12):3795-801. PubMed ID: 1281186 [TBL] [Abstract][Full Text] [Related]
19. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Salomon B; Bluestone JA Annu Rev Immunol; 2001; 19():225-52. PubMed ID: 11244036 [TBL] [Abstract][Full Text] [Related]
20. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle. Giguère JF; Bounou S; Paquette JS; Madrenas J; Tremblay MJ J Virol; 2004 Jun; 78(12):6222-32. PubMed ID: 15163715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]